Ramos Alberto R, Figueredo Pedro, Shafazand Shirin, Chediak Alejandro D, Abreu Alexandre R, Dib Salim I, Torre Carlos, Wallace Douglas M
Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, United States.
Sleep Disorders Center, Miller School of Medicine, Bascom Palmer Eye Institute, University of Miami, Miami, FL, United States.
Front Neurol. 2017 Dec 5;8:659. doi: 10.3389/fneur.2017.00659. eCollection 2017.
Obstructive sleep apnea (OSA) is a chronic and heterogeneous disorder that leads to early mortality, stroke, and cardiovascular disease (CVD). OSA is defined by the apnea-hypopnea index, which is an index of OSA severity that combines apneas (pauses in breathing) and hypopneas (partial obstructions in breathing) associated with hypoxemia. Yet, other sleep metrics (i.e., oxygen nadir, arousal frequency), along with clinical symptoms and molecular markers could be better predictors of stroke and CVD outcomes in OSA. The recent focus on personalized medical care introduces the possibility of a unique approach to the treatment of OSA based on its phenotypes, defined by pathophysiological mechanisms and/or clinical presentation. We summarized what is known about OSA and its phenotypes, and review the literature on factors or intermediate markers that could increase stroke risk and CVD in patients with OSA. The OSA phenotypes where divided across three different domains (1) clinical symptoms (i.e., daytime sleepiness), (2) genetic/molecular markers, and (3) experimental data-driven approach (e.g., cluster analysis). Finally, we further highlight gaps in the literature framing a research agenda.
阻塞性睡眠呼吸暂停(OSA)是一种慢性异质性疾病,可导致早亡、中风和心血管疾病(CVD)。OSA由呼吸暂停低通气指数定义,该指数是OSA严重程度的指标,它结合了与低氧血症相关的呼吸暂停(呼吸暂停)和低通气(部分呼吸阻塞)。然而,其他睡眠指标(即氧最低点、觉醒频率)以及临床症状和分子标志物可能是OSA患者中风和CVD结局的更好预测指标。最近对个性化医疗的关注引入了一种基于其表型的独特OSA治疗方法的可能性,该表型由病理生理机制和/或临床表现定义。我们总结了关于OSA及其表型的已知信息,并回顾了关于可能增加OSA患者中风风险和CVD的因素或中间标志物的文献。OSA表型分为三个不同领域:(1)临床症状(即日间嗜睡),(2)遗传/分子标志物,以及(3)实验数据驱动方法(例如聚类分析)。最后,我们进一步强调了构成研究议程的文献中的差距。